Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

2025年1月8日，Viking ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

美股今年开局强劲，由于美国经济充满韧性、通胀压力有所缓和、企业盈利状况改善，以及市场对美联储降息的预期，标普500指数一季度大涨10%。当然，投资者对人工智能的热情也起到了重要作用，推动大型科技公司和相关概念股走高。

On Thursday, H.C. Wainwright adjusted its price target on TransCode Therapeutics Inc (NASDAQ: RNAZ) significantly upwards, from $3.00 to $20.00, while maintaining a ...

He arrived with a bang, fueled by a vow to bite kneecaps. Three years later, he has transformed the perpetually dysfunctional Detroit Lions into one of the finest franchises in all of football. And, ...